NCT06634303 (Post-MECC) is a NA clinical trial of Brain cooling in Acute Ischemic Stroke, sponsored by Hybernia Medical.

Who is sponsoring NCT06634303?

NCT06634303 is sponsored by Hybernia Medical.

What drugs are being tested in NCT06634303?

Interventions in NCT06634303: Brain cooling.

What condition does NCT06634303 study?

NCT06634303 studies Acute Ischemic Stroke.

Is NCT06634303 still recruiting?

NCT06634303 is currently completed. Last updated 17 March 2026.

Last reviewed 2026-03-17 · How we verify

NCT06634303: Post-MECC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hybernia Medical Post-Mechanical Thrombectomy Cerebral Cooling in Stroke

Completed NA Last updated 17 March 2026

What this trial tests

NA trial testing Brain cooling in Acute Ischemic Stroke in 8 participants. Completed in 20 February 2026.

Timeline

1 June 2025

Primary endpoint
1 October 2025

20 February 2026

Quick facts

Lead sponsor	Hybernia Medical
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	8
Start date	1 June 2025
Primary completion	1 October 2025
Estimated completion	20 February 2026
Sites	1 location across Spain

Drugs / interventions tested

Brain cooling

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

Hybernia Medical — full company profile →

Who can join

Adults 18 to 89, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reducing the temperature of tissue or organs (hypothermia) produces a protective state, through multiple molecular mechanisms, against adverse effects that arise from disrupted organ blood flow, e.g. in acute ischemic stroke (AIS). AIS is often caused by a blood clot that occludes a brain artery which, in turn disrupts brain blood flow. In large vessel occlusions, the current standard includes mechanical thrombectomy (MT), a minimally-invasive procedure that aims at removing the clot via endovascular means. In this case, brain cooling can lead to protection (neuroprotection) not only from the adverse effects of stroke/ischemia itself, but also from complications arising from sudden re-opening of the blocked artery through primary treatment, MT. This potential complication of MT is called reperfusion injury. In this first-in-human investigational deivce study, Hybernia Medical's endovascular brain cooling system will be applied in acute ischemic stroke patients undergoing MT. Post-MT, selective brain hypothermia will be induced and maintained over 30 minutes. Endpoints of this study include, clinical safety, device performance/usability, and clinical outcome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Abstract 500: Selective Endovascular Brain Cooling Following Mechanical Thrombectomy in Acute Ischemic Stroke. Hybernia Medical First‐in‐Human Investigation.
Ribo M, Rodrigo‐Gispert M, Requena M, de Dios M, et al · · 2025

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06634303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hybernia Medical
Last refreshed: 17 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06634303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing